COVID-19 Acute Respiratory Distress Syndrome
Conditions
Brief summary
The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.
Interventions
DRUGLidocaine
Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Sponsors
Sheikh Zayed Medical College
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Covid-19 positive * Moderate to severe ARDS
Exclusion criteria
* patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cough suppression | within five minutes of initiation of treatment it will be assessed | it will be assessed by using cough severity score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| correction of hypoxia | immediately before and after intervention | it will be assessed by PaO2 |
Countries
Pakistan
Contacts
Primary Contactsairah s sadaf, FCPS
Outcome results
None listed